CytomX Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de CytomX Therapeutics es Sean McCarthy , nombrado en Aug 2011, tiene una permanencia de 13.25 años. compensación anual total es $2.61M, compuesta por 25% salario y 75% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.71% de las acciones de la empresa, por valor de €470.21K. La antigüedad media del equipo directivo y de la junta directiva es de 3.6 años y 4.8 años, respectivamente.

Información clave

Sean McCarthy

Chief Executive Officer (CEO)

US$2.6m

Compensación total

Porcentaje del salario del CEO	25.0%
Permanencia del CEO	13.3yrs
Participación del CEO	0.7%
Permanencia media de la dirección	3.6yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sean McCarthy en comparación con los beneficios de CytomX Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$14m
Jun 30 2024	n/a	n/a	US$11m
Mar 31 2024	n/a	n/a	US$17m
Dec 31 2023	US$3m	US$652k	-US$569k
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$42m
Mar 31 2023	n/a	n/a	-US$71m
Dec 31 2022	US$3m	US$623k	-US$99m
Sep 30 2022	n/a	n/a	-US$149m
Jun 30 2022	n/a	n/a	-US$143m
Mar 31 2022	n/a	n/a	-US$132m
Dec 31 2021	US$4m	US$616k	-US$116m
Sep 30 2021	n/a	n/a	-US$72m
Jun 30 2021	n/a	n/a	-US$64m
Mar 31 2021	n/a	n/a	-US$61m
Dec 31 2020	US$3m	US$595k	-US$65m
Sep 30 2020	n/a	n/a	-US$54m
Jun 30 2020	n/a	n/a	-US$63m
Mar 31 2020	n/a	n/a	-US$76m
Dec 31 2019	US$4m	US$575k	-US$133m
Sep 30 2019	n/a	n/a	-US$99m
Jun 30 2019	n/a	n/a	-US$99m
Mar 31 2019	n/a	n/a	-US$83m
Dec 31 2018	US$5m	US$550k	-US$85m
Sep 30 2018	n/a	n/a	-US$52m
Jun 30 2018	n/a	n/a	-US$39m
Mar 31 2018	n/a	n/a	-US$50m
Dec 31 2017	US$3m	US$500k	-US$43m

Compensación vs. Mercado: La compensación total de Sean($USD2.61M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD472.15K).

Compensación vs. Ingresos: La compensación de Sean ha sido consistente con los resultados de la empresa en el último año.

CEO

Sean McCarthy (57 yo)

13.3yrs

Permanencia

US$2,611,138

Compensación

Dr. Sean A. McCarthy, D.Phil., serves as Independent Director at OncoResponse, Inc. since August 2021. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since August 2011 and has been it...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sean McCarthy	Chairman & CEO	13.3yrs	US$2.61m	0.71% € 470.2k
Marcia Belvin	Senior VP & Chief Scientific Officer	1.8yrs	US$1.21m	0.085% € 56.5k
Jeffrey Landau	Senior VP	3.6yrs	US$1.05m	0.079% € 52.6k
Christopher Ogden	Chief Financial Officer	2.2yrs	sin datos	0.039% € 25.7k
Lloyd Rowland	Senior VP	6.5yrs	US$1.21m	0.10% € 66.2k
Danielle Olander-Moghadassian	Senior VP & Chief Human Resources Officer	no data	sin datos	sin datos
Leslie Robbins	Senior Vice President of Intellectual Property	5.8yrs	sin datos	sin datos
Yu-Waye Chu	Chief Medical Officer	1.3yrs	sin datos	sin datos
Dawn Benson	Senior Vice President of Quality & Product Manufacturing	1.8yrs	sin datos	sin datos
Hoyoung Huh	Special Advisor to Chief Executive Officer	no data	US$273.54k	sin datos

3.6yrs

Permanencia media

55.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 6C1 se considera experimentado (3.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sean McCarthy	Chairman & CEO	13.3yrs	US$2.61m	0.71% € 470.2k
Elaine Jones	Independent Director	5.5yrs	US$75.12k	0.0066% € 4.4k
John Lambert	Member of Scientific Advisory Board	4.8yrs	sin datos	sin datos
Louis Weiner	Member of Scientific Advisory Board	no data	sin datos	sin datos
Mani Mohindru	Independent Director	3.9yrs	US$78.62k	0% € 0
James Meyers	Independent Director	5.9yrs	US$77.12k	0% € 0
Matthew Young	Lead Independent Director	9.2yrs	US$105.12k	0% € 0
Halley Gilbert	Independent Director	4.6yrs	US$80.62k	0% € 0
W. Kavanaugh	Member of Scientific Advisory Board	3.9yrs	US$8.03m	sin datos
Alan Ashworth	Independent Director	3.2yrs	US$69.12k	0% € 0
Charles Sentman	Member of Scientific Advisory Board	4.8yrs	sin datos	sin datos
Lisa Coussens	Member of Scientific Advisory Board	1.8yrs	sin datos	sin datos

4.8yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de 6C1 se considera experimentada (4.8 años de antigüedad promedio).

CytomX Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer

CytomX Therapeutics, Inc., Annual General Meeting, May 15, 2024

CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors

CytomX Therapeutics, Inc. Appoints Yu-Waye Chu as Chief Medical Officer

High number of new and inexperienced directors

CytomX Therapeutics, Inc. Announces Executive Changes

Recent updates

Third quarter 2024 earnings released: EPS: US$0.067 (vs US$0.037 in 3Q 2023)

CytomX Therapeutics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Investor sentiment improves as stock rises 18%

Second quarter 2024 earnings released: US$0.077 loss per share (vs US$0.016 loss in 2Q 2023)

New minor risk - Market cap size

CytomX Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Investor sentiment improves as stock rises 15%

Investor sentiment deteriorates as stock falls 15%

CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer

Investor sentiment deteriorates as stock falls 54%

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

First quarter 2024 earnings released: EPS: US$0.17 (vs US$0.05 loss in 1Q 2023)

CytomX Therapeutics, Inc. to Report Q1, 2024 Results on May 08, 2024

CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors

CytomX Therapeutics, Inc., Annual General Meeting, May 15, 2024

CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors

Full year 2023 earnings released: US$0.008 loss per share (vs US$1.51 loss in FY 2022)

CytomX Therapeutics, Inc. to Report Q4, 2023 Results on Mar 11, 2024

New minor risk - Market cap size

CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b

New minor risk - Profitability

Forecast breakeven date pushed back to 2024

Third quarter 2023 earnings released: EPS: US$0.037 (vs US$0.35 loss in 3Q 2022)

Forecast to breakeven in 2023

CytomX Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CytomX Therapeutics, Inc. Presents Preclinical Profile of EpCAM-Directed Antibody Drug Conjugate CX-2051 at 2023 World ADC Conference

CytomX Therapeutics, Inc. announced that it has received $30 million in funding

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.016 loss per share (vs US$0.37 loss in 2Q 2022)

CytomX Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CytomX Therapeutics, Inc. Appoints Yu-Waye Chu as Chief Medical Officer

New minor risk - Market cap size

First quarter 2023 earnings released: US$0.05 loss per share (vs US$0.36 loss in 1Q 2022)

Full year 2022 earnings released: US$1.51 loss per share (vs US$1.81 loss in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.35 loss per share (vs US$0.35 loss in 3Q 2021)

CytomX Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

CytomX Therapeutics, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.37 loss per share (vs US$0.30 loss in 2Q 2021)

CytomX Therapeutics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Cytomx Therapeutics, Inc. to Terminate Carlos Campoy as Chief Financial Officer, Effective as of September 30, 2022

CytomX Therapeutics, Inc. Announces Phase 2 Results for Praluzatamab Ravtansine in Breast Cancer

CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors

First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.26 loss in 1Q 2021)

High number of new directors

Cytomx Therapeutics Announces Retirement of John A. Scarlett from Board of Directors and Chair of the Compensation Committee and A Member of the Audit Committee

CytomX Therapeutics, Inc., Annual General Meeting, Jun 15, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

CytomX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Cytomx Therapeutics, Inc. Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer

CytomX Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors

CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029

Third quarter 2021 earnings released: US$0.35 loss per share (vs US$0.32 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.30 loss per share (vs US$0.34 loss in 2Q 2020)

CytomX Therapeutics, Inc. Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research

First quarter 2021 earnings released: US$0.26 loss per share (vs US$0.27 profit in 1Q 2020)

Full year 2020 earnings released: US$0.71 loss per share (vs US$2.26 loss in FY 2019)

Revenue beats expectations

CytomX Therapeutics, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day high: €7.42

New 90-day high: €6.65

CytomX Therapeutics, Inc. Appoints Dr. Mani Mohindru to Board of Directors

New 90-day high: €6.60

Revenue beats expectations

Third quarter 2020 earnings released: US$0.32 loss per share

CytomX Therapeutics, Inc. Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate

CytomX Therapeutics, Inc. to Report Q3, 2020 Results on Nov 05, 2020

CytomX Therapeutics, Inc. Announces Planned Retirement of W. Michael Kavanaugh, Chief Scientific Officer, Head of Research and Non-Clinical Development on December 1, 2020

New 90-day low - €5.55